- Home
- RDW vs ITOS Comparison
RDW vs ITOS Comparison
Compare RDW & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDW
- ITOS
- Stock Information
- Founded
- RDW 2020
- ITOS 2011
- Country
- RDW United States
- ITOS United States
- Employees
- RDW N/A
- ITOS N/A
- Industry
- RDW Military/Government/Technical
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDW Industrials
- ITOS Health Care
- Exchange
- RDW Nasdaq
- ITOS Nasdaq
- Market Cap
- RDW 800.5M
- ITOS 283.9M
- IPO Year
- RDW N/A
- ITOS 2020
- Fundamental
- Price
- RDW $13.93
- ITOS $7.30
- Analyst Decision
- RDW Strong Buy
- ITOS Strong Buy
- Analyst Count
- RDW 5
- ITOS 3
- Target Price
- RDW $10.95
- ITOS $21.33
- AVG Volume (30 Days)
- RDW 855.7K
- ITOS 459.3K
- Earning Date
- RDW 11-06-2024
- ITOS 11-12-2024
- Dividend Yield
- RDW N/A
- ITOS N/A
- EPS Growth
- RDW N/A
- ITOS N/A
- EPS
- RDW N/A
- ITOS N/A
- Revenue
- RDW $298,026,000.00
- ITOS $35,000,000.00
- Revenue This Year
- RDW $28.47
- ITOS $271.18
- Revenue Next Year
- RDW $18.23
- ITOS N/A
- P/E Ratio
- RDW N/A
- ITOS N/A
- Revenue Growth
- RDW 27.35
- ITOS N/A
- 52 Week Low
- RDW $2.68
- ITOS $7.09
- 52 Week High
- RDW $15.25
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- RDW 61.81
- ITOS 29.34
- Support Level
- RDW $12.27
- ITOS $7.44
- Resistance Level
- RDW $14.09
- ITOS $7.96
- Average True Range (ATR)
- RDW 1.25
- ITOS 0.38
- MACD
- RDW -0.09
- ITOS -0.07
- Stochastic Oscillator
- RDW 84.94
- ITOS 5.41
About RDW Redwire Corporation
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's Heritage plus Innovation strategy enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.